騰景科技(688195.SH):擬設立控股子公司開展“合肥功能晶體材料與器件建設項目”
格隆匯5月29日丨騰景科技(688195.SH)公佈,為加強公司在功能晶體材料和功能晶體器件方面的研發和製造能力,豐富公司晶體及器件的產品品類,拓展激光和生物醫療的光學業務,公司擬與安徽晶湖創業投資合夥企業共同出資3000萬元設立控股子公司“合肥眾波功能材料有限公司”,並由控股子公司與合肥高新技術產業開發區管理委員會投資招商中心簽署《功能晶體材料與器件建設項目投資合作協議書》及《功能晶體材料與器件建設項目投資合作補充協議書》,開展“合肥功能晶體材料與器件建設項目”。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.